Page 38 - Read Online

Page 12 of 14 Rabadi et al. J Cancer Metastasis Treat 2022;8:24 https://dx.doi.org/10.20517/2394-4722.2022.06

19. Lines JL, Pantazi E, Mak J, et al. VISTA is an immune checkpoint molecule for human T cells. Cancer Res 2014;74:1924-32. DOI
PubMed PMC
+
20. Flies DB, Han X, Higuchi T, et al. Coinhibitory receptor PD-1H preferentially suppresses CD4 T cell-mediated immunity. J Clin
Invest 2014;124:1966-75. DOI PubMed PMC
21. Tanbouly MA, Croteau W, Noelle RJ, Lines JL. VISTA: a novel immunotherapy target for normalizing innate and adaptive
immunity. Semin Immunol 2019;42:101308. DOI
22. El Tanbouly MA, Schaafsma E, Smits NC, et al. VISTA Re-programs macrophage biology through the combined regulation of
tolerance and anti-inflammatory pathways. Front Immunol 2020;11:580187. DOI PubMed PMC
23. Wang L, Le Mercier I, Putra J, et al. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with
predisposition to the development of autoimmunity. Proc Natl Acad Sci USA 2014;111:14846-51. DOI PubMed PMC
24. Ceeraz S, Sergent PA, Plummer SF, et al. VISTA deficiency accelerates the development of fatal murine lupus nephritis. Arthritis
Rheumatol 2017;69:814-25. DOI PubMed PMC
25. Sergent PA, Plummer SF, Pettus J, et al. Blocking the VISTA pathway enhances disease progression in (NZB × NZW) F1 female
mice. Lupus 2018;27:210-6. DOI PubMed PMC
26. Li N, Xu W, Yuan Y, et al. Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. Sci Rep
2017;7:1485. DOI PubMed PMC
27. Flies DB, Higuchi T, Chen L. Mechanistic assessment of PD-1H coinhibitory receptor-induced T Cell tolerance to allogeneic
antigens. J Immunol 2015;194:5294-304. DOI PubMed PMC
28. Liu J, Yuan Y, Chen W, et al. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc
Natl Acad Sci USA 2015;112:6682-7. DOI PubMed PMC
29. Shrestha R, Prithviraj P, Anaka M, et al. Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular
carcinoma. Front Oncol 2018;8:269. DOI PubMed PMC
30. Zhang M, Pang HJ, Zhao W, et al. VISTA expression associated with CD8 confers a favorable immune microenvironment and better
overall survival in hepatocellular carcinoma. BMC Cancer 2018;18:511. DOI PubMed PMC
31. Böger C, Behrens HM, Krüger S, Röcken C. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and
associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy? Oncoimmunology 2017;6:e1293215. DOI
PubMed PMC
32. Schoop H, Bregenzer A, Halske C, et al. Therapy resistance in neoadjuvantly treated gastric cancer and cancer of the
gastroesophageal junction is associated with an increased expression of immune checkpoint inhibitors-comparison against a therapy
naïve cohort. Transl Oncol 2020;13:165-76. DOI PubMed PMC
33. Villarroel-Espindola F, Yu X, Datar I, et al. Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy
target in human non-small cell lung cancer. Clin Cancer Res 2018;24:1562-73. DOI PubMed PMC
34. Liao H, Zhu H, Liu S, Wang H. Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the
advanced stage and presence of lymph node metastasis in ovarian cancer. Oncol Lett 2018;16:3465-72. DOI PubMed PMC
35. Mulati K, Hamanishi J, Matsumura N, et al. VISTA expressed in tumour cells regulates T cell function. Br J Cancer 2019;120:115-
27. DOI PubMed PMC
36. Zong L, Zhang M, Wang W, Wan X, Yang J, Xiang Y. PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic
neoplasia. Histopathology 2019;75:421-30. DOI PubMed
37. Kuklinski LF, Yan S, Li Z, et al. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma
correlates with poor disease-specific survival. Cancer Immunol Immunother 2018;67:1113-21. DOI PubMed
38. Choi JW, Kim YJ, Yun KA, et al. The prognostic significance of VISTA and CD33-positive myeloid cells in cutaneous melanoma
and their relationship with PD-1 expression. Sci Rep 2020;10:14372. DOI PubMed PMC
39. Wu L, Deng WW, Huang CF, et al. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict
survival in human oral squamous cell carcinoma. Cancer Immunol Immunother 2017;66:627-36. DOI PubMed
40. Hou Z, Pan Y, Fei Q, et al. Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer. J
Cancer Res Clin Oncol 2021;147:517-31. DOI PubMed PMC
41. Ghouzlani A, Lakhdar A, Rafii S, Karkouri M, Badou A. The immune checkpoint VISTA exhibits high expression levels in human
gliomas and associates with a poor prognosis. Sci Rep 2021;11:21504. DOI PubMed PMC
42. He XL, Zhou Y, Lu HZ, Li QX, Wang Z. Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis. Sci
Rep 2020;10:2662. DOI PubMed PMC
43. Loeser H, Kraemer M, Gebauer F, et al. The expression of the immune checkpoint regulator VISTA correlates with improved overall
survival in pT1/2 tumor stages in esophageal adenocarcinoma. Oncoimmunology 2019;8:e1581546. DOI PubMed PMC
44. Cao X, Ren X, Zhou Y, et al. VISTA expression on immune cells correlates with favorable prognosis in patients with triple-negative
breast cancer. Front Oncol 2020;10:583966. DOI PubMed PMC
45. Hernandez-Martinez JM, Vergara E, Zatarain-Barrón ZL, Barrón-Barrón F, Arrieta O. VISTA/PD-1H: a potential target for non-
small cell lung cancer immunotherapy. J Thorac Dis 2018;10:6378-82. DOI PubMed PMC
46. Zong L, Zhou Y, Zhang M, Chen J, Xiang Y. VISTA expression is associated with a favorable prognosis in patients with high-grade
serous ovarian cancer. Cancer Immunol Immunother 2020;69:33-42. DOI PubMed PMC
47. Xie S, Huang J, Qiao Q, et al. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors.